WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
NCPA's annual chamber music festival to kick offHyderabad pulls off 1Marlins slip past Rockies 5North Carolina boy, 18, wins $2million on one of the first scratchPeter Oosterhuis, Ryder Cup stalwart and CBS announcer, dies at 75Shanghai citizens average 12 books per yearPhotography exhibition by Italian journalist opens in Xi'anScreenwriter Chen Yu amazed by young filmmakersImperial Chinese wine jar stolen from Belgian museumChina's new energy competitiveness honed through genuine expertise
2.0143s , 6515.921875 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Earth Echo news portal